Abstract:PURPOSE:Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone that has been approved for the treatment of community-acquired pneumonia (CAP) in adults. The goals of this study were to evaluate the pharmacokinetic (PK) and population PK parameters of nemonoxacin and to provide the appropriate dose adjustment recommendations for patients with hepatic impairment. METHODS:An open-label, single-dose, parallel group (moderate hepatic impairment group and healthy control group) PK study of nemonoxacin was conducted. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to detect the unchanged nemonoxacin concentration in blood and urine samples. The nonlinear mixed effects modeling tool NONMEN (version 7.3) was used to conduct the population PK analysis. The paired-t test was conducted to compare the PK parameters of the hepatic impairment group and the healthy control group by SPSS (Version 17.0). FINDINGS:Ten subjects for each group were enrolled into the PK study. The PK parameters as well as the plasma concentration-time and logarithmic concentration-time profiles after taking a 500-mg single dose of nemonoxacin showed few differences between the two groups (P > 0.05). The mean areas under the plasma concentration vs. time curve from 0 to 72 h (AUC0-72 h) of the moderate hepatic impairment group and the healthy control group in the nemonoxacin PK study were 58.50 (17.30) mg·h/mL and 49.74 (10.16) mg·h/mL, respectively, giving a mean (SD) AUC0-72 h ratio of 1.15 (0.42) with a 90% CI of 0.91-1.39. A 3- compartment model was considered to be the best model for the data, especially in fitting the plasma point at low drug concentrations. Covariate analysis indicated that weight affected CL/F, V1/F, and V3/F and that eGFR only affected CL/F in the power function model, while gender affected V3/F in the linear model by forward selection and backward deletion. IMPLICATIONS:The population PK parameters of nemonoxacin were evaluated in patients with hepatic impairment. The hepatic function did not have a significant impact on the PK parameters of nemonxacin, but renal function was a meaningful covariate that is consistent with its PK characteristics. In this study, nemonoxacin was well tolerated in the patients with moderate hepatic impairment as well as in the healthy subjects. Based on these data, it is not necessary to consider dose adjustment of nemonoxacin in patients with mild or moderate hepatic impairment. ClinicalTrials.gov identifier: NCT02604498.

A rapid and robust method for determination of nemonoxacin in human plasma and urine

A Liquid Chromatography-Tandem Mass Spectrometry Assay for the Determination of Nemonoxacin (Tg-873870), A Novel Nonfluorinated Quinolone, in Human Plasma and Urine and Its Application to A Single-Dose Pharmacokinetic Study in Healthy Chinese Volunteers

Validation of a fast and reliable liquid chromatography tandem mass spectrometry for simultaneous quantitation of Voriconazole, Posaconazole and Linezolid in human serum

Development and Validation of a Rapid and Robust LC-MS/MS Method for Quantifi-Cation of a New Oxazolidinone Antibiotic MRX-I in Human Plasma and Urine

A Rapid Method With Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry For Simultaneous Determination Of Five Type B Trichothecenes In Traditional Chinese Medicines

Rapid and sensitive liquid chromatography tandem mass spectrometry method for the quantification of ambroxol in human plasma.

A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Controlled, Phase 3 Clinical Trial Assessing the Efficacy and Safety of Intravenous Nemonoxacin Malate Versus Levofloxacin for Community-Acquired Pneumonia in Adult Patients

Simultaneous determination of amoxicillin and ambroxol in human plasma by LC-MS/MS: validation and application to pharmacokinetic study

Determination of Levonorgestrel in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry

Development and validation of an LC–MS/MS method for the quantitative analysis of the adenosine A2a receptor antagonist NIR178 and its monohydroxy metabolite in human plasma: Application to clinical pharmacokinetics

A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study.

Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment.

A simple and sensitive ultra‐high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX‐548 in monkey plasma: Method validation and application to pharmacokinetic study

Rapid and Simultaneous Quantitation of Amoxicillin and Clavulanic Acid in Human Plasma and Urine by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of polymyxin B1 and B2

A simple and sensitive liquid chromatography triple quadrupole mass spectrometry method for the determination of XL092 in monkey plasma and its application to pharmacokinetic study

LC-MS/MS Method for Therapeutic Drug Monitoring of Polymyxin B in Human Plasma

Simultaneous quantification of niacin and its three main metabolites in human plasma by LC-MS/MS.

Determination of Antofloxacin in Human Plasma by Solid Phase Extraction-Liquid Chromatography-Mass Spectrometry

Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers.

Sensitive liquid chromatography/mass spectrometry assay for the quantification of azithromycin in human plasma.